Kura Oncology KURA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.64M+31.4% | $67.48M+25.2% | $63.62M+57.4% | $56.34M+109% | $54.52M+305% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $260.36M+37.3% | $251.07M+47.7% | $238.93M+59.0% | $212.73M+54.3% | $189.67M+50.2% | ||
| —— | —— | —— | —— | $80.67M+41.0% | ||
| —— | —— | —— | —— | —— | ||
| -$317.75M-56.2% | -$303.63M-57.2% | -$239.82M-13.0% | -$219.71M-13.4% | -$203.44M-13.8% | ||
| -443.5%-70.4pp | -449.9%-91.4pp | -377%+148pp | -390%+329pp | -373.2%+954pp | ||
| $1.47M-8.5% | $1.51M-6.6% | $1.57M-2.5% | $1.59M-0.9% | $1.6M+1.3% | ||
| $24.72M-2.7% | $26.77M+17.2% | $26.75M+24.1% | $26.37M+32.2% | $25.4M+47.8% | ||
| $23.26M-2.3% | $25.26M+19.0% | $25.18M+26.2% | $24.78M+35.1% | $23.8M+52.5% | ||
| -$294.49M-63.9% | -$278.37M-61.9% | -$214.64M-11.3% | -$194.93M-10.3% | -$179.64M-9.5% | ||
| —— | —— | —— | —— | $1.74M+245% | ||
| -$294.57M-62.0% | -$278.67M-60.2% | -$216.88M-9.8% | -$197.17M-8.5% | -$181.89M-8.2% | ||
| -411.2%-77.6pp | -412.9%-90.1pp | -340.9%+148pp | -350%+325pp | -333.6%+914pp | ||
| -$3.35-59.5% | -$3.18-56.7% | -$2.48-5.1% | -$2.26-1.3% | -$2.10+3.2% | ||
| -$3.35-59.5% | -$3.18-56.7% | -$2.48-5.1% | -$2.26-1.3% | -$2.10+3.2% | ||
| 351.5M+1.3% | 350.3M+1.9% | 348.8M+5.5% | 348.1M+8.4% | 347.2M+14.1% | ||
| 351.5M+1.3% | 350.3M+1.9% | 348.8M+5.5% | 348.1M+8.4% | 347.2M+14.1% | ||
| —— | $57K— | $42.75K— | $28.5K— | $14.25K— | ||
| -$295.92M-64.3% | -$278.41M-61.9% | -$217.08M-12.5% | -$196M-10.7% | -$180.1M-10.5% | ||
| $24.72M-2.7% | $26.77M+17.2% | $26.75M+24.1% | $26.37M+32.2% | $25.4M+47.8% | ||
| —— | —— | —— | —— | —— | ||
| $71.64M+31.4% | $67.48M+25.2% | $63.62M+57.4% | $56.34M+109% | $54.52M+305% | ||
| -$317.75M-56.2% | -$303.63M-57.2% | -$239.82M-13.0% | -$219.71M-13.4% | -$203.44M-13.8% | ||
| -$316.6M-56.3% | -$302.6M-57.3% | -$238.99M-13.1% | -$218.83M-13.4% | -$202.59M-13.9% | ||
| -$316.6M-56.3% | -$302.6M-57.3% | -$238.99M-13.1% | -$218.83M-13.4% | -$202.59M-13.9% | ||
| -441.9%-70.4pp | -448.4%-91.4pp | -375.7%+147pp | -388.4%+328pp | -371.6%+949pp | ||
| -$317.75M-56.2% | -$303.63M-57.2% | -$239.82M-13.0% | -$219.71M-13.4% | -$203.44M-13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kura Oncology's revenue?
- Kura Oncology (KURA) generated $71.6M in revenue over the trailing twelve months, up 31.4% year over year.
- Is Kura Oncology profitable?
- Kura Oncology is not currently profitable: it reported a net loss of $294.6M over the trailing twelve months, a -411.2% net margin.
- What is Kura Oncology's earnings per share?
- Kura Oncology's diluted EPS over the trailing twelve months is $-3.35.
- Where does Kura Oncology's income statement data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
